Originally considered the therapy of last resort, interventional oncology has been a fast growing field for the last decade and is emerging as a recognised interventional radiology sub-specialty.
Many minimally-invasive, imaging-guided procedures are replacing more traditional open surgical techniques for treating solid tumours in a variety of organs – most often in the liver (primary and metastatic tumours), lung and kidney[1].
Onco suite is a combination of the Azurion platform, interventional solutions, workflow options, education, and services.
Interventional oncology has evolved from a niche specialty to a well-established treatment alternative for various types of cancers.
Strong clinical evidence supports procedures such as transcatheter embolisation for primary liver cancer and metastases, and focal tumour ablation therapy.
Adoption of chemo/radioembolisation techniques such as TACE and SIRT drives the need for standardisation and efficiency. Case after case, you must reliably and consistently locate the tumour(s), identify all feeder vessels, and plan/execute the appropriate interventional approach.
Onco suite provides tools to help you:
EmboGuide supports you in maximising the efficacy of your TACE procedures as it potentially enhances your sensitivity, reduces false positives and maximises inter-reader agreement [4]. It provides efficient, workflow-based live 3D guidance with automatic feeder detection [5].
Percutaneous ablation (radiofrequency, microwave, and cryoablation) is a well-established minimally invasive treatment of kidney, liver, lung and bone tumours. The key is gaining a clear understanding of the tumour size, needle ablation area, and optimal path to the target.
Onco suite provides tools to help you:
Azurion Onco suite offers a number of workflow innovations designed to help oncology teams work efficiently and consistently, while maintaining a single-minded focus on the patient and keeping radiation dose low during interventions.
Work with confidence.
This is just one of the many improvements in lab performance achieved by the Interventional Vascular Department at St. Antonius Hospital after installing the Azurion system. The first Azurion lab performance study achieved impressive results which have been verified by an independent third party.
*SmartCT is 510(k) pending in the U.S.A. Not available for sales in the U.S.A
** As described in the SmartCT Instructions for Use
1. Medtech 360 2016-2019, Millennium Research Group
2. Schernthaner RE et al, Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization, Radiology. 2015; 277(3):833–4.
3. Loffroy R, et al. Comparing the detectability of hepatocellular carcinoma by C-arm dual-phase cone-beam computed tomography during hepatic arteriography with conventional contrast-enhanced magnetic resonance imaging. Cardiovasc Intervent Radiol. 2012;35(1):97-104.
4. Chiaradia et al, J J,Sensitivity and Reproducibility of AFD Software for HCC, Vasc Interv Radiol 2018;29:425-431.
5. Miyayama S, et al. Identification of small hepatocellular carcinoma and tumour-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2013; 24(4):501-8.
6. Trunz L. et al, Investigation of Radiation Dose Estimates and Image Quality Between Commercially Available Interventional Fluoroscopy Systems for Fluoroscopically Guided Interventional Procedures, Academic Radiology, in press, 2020
7. Levi E.B. et al, First Human Experience with Directly Image-able Iodinated Embolization Microbeads, Cardiovascular and interventional radiology, vol 39, issue 8, 1177-1186, 2016
8. Floridi C et al, Percutaneous needle biopsy of mediastinal masses under C-arm conebeam CT guidance: diagnostic performance and safety, Medical Onocology, 2017; 34(4): 1-7
9. Abi-jaoudeh et al , Cone Beam vs Conventional CT Navigation for Image-Guided Biopsy, J VascIntervRadio; 2016; 27: 1342–1349.
10. Percutaneous transthoracic needle biopsy of small (1 cm) lung nodules under C-arm cone-beam CT virtual navigation guidance; Ji Yung Choo Eur Radiol; 2013; 23:712–719.
11. Philips whitepaper 4522 991 30501; Reduction of procedure time by 17% with Philips Azurion in independent verified study. Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.
12. In 18 individual comparative studies, Philips ClarityIQ was associated with reductions in patient radiation exposure. For the full list of clinical peer-reviewed papers go to www.philips.co.uk/healthcare/resources/landing/alluraclarity-clinically-proven
The results of the application of dose reduction techniques will vary depending on the clinical task, patient size, anatomical location and clinical practice. The interventional radiologist assisted by a physicist as necessary has to determine the appropriate settings for each specific clinical task. Results based on DSA dose area product per frame from a single center prospective randomized study on 48 patients. DSA runs for Allura Xper with ClarityIQ and Allura Xper without ClarityIQ were randomly acquired on the same patient under same condition of geometry, field of view and injection protocol. Image quality was based on subjective assessment (side-by-side, equal or superior than the other, blinded review by 5 independent radiologists).
